Skip to content

Alloimmune Response to Citrullinated Shared Epitope Sequence in Patients With Rheumatoid Arthritis

Alloimmune Model in Rheumatoid Arthritis. Alloimmune Response to Citrullinated Shared Epitope Sequence in Patients With Rheumatoid Arthritis.Alloimmune Response to Citrullinated Shared Epitope Sequence in Patients With Rheumatoid Arthritis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03506035
Acronym
ABSEC
Enrollment
200
Registered
2018-04-23
Start date
2018-09-01
Completion date
2020-09-01
Last updated
2018-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Shared epitope, HLA-DRB1, Citrullinated peptides, Autoantibodies

Brief summary

Rheumatoid arthritis (RA) is an autoimmune and sistemic disease,characterized by joint sinovitis and the production of autoantibodies (Ab). The Ab against citrullinated peptides (ACPA) are the most specific (92-98%), and high sensitivity (75-81%) and they are of prognostic value. ACPA are already in the beginning of the disease in most cases, having been found years before its onset. Recent studies have suggested that ACPA may have a role in perpetuating inflammation, in the generation of bone erosions and in pain in RA. Citrullination is a post-translational modification mediated by the PAD, which transforms an arginine into a citrulline. In vivo, this enzyme acts in proinflammatory environments. Despite being widely studied, none of the natural citrullinated substrates have been shown to be the triggering and/or perpetuating factor in the response of B cells in RA, understanding this response as the production of ACPA. In fact, the most specific and sensitive commercial test for the detection of ACPA uses synthetic peptides protected by a patent. In the other hand, the genetic factor that most increases susceptibility to develop RA is a shared sequence of aminoacids (QKRAA, QRRAA i RRRAA), in the HLA-DRB1 gene, known as the shared epitope (SE). Also, SE, confers prognostic value, and is associated with the presence of ACPA. These SE sequences contain arginines (R), which are susceptible to be citrullinated by the PAD enzyme. We propose the hypothesis that citrullinated SE act as an antigen capable of activating the inflammatory response mediated by B and T cells in RA. The recognition of an HLA as a foreign one, would originate an answer of alloimmune type, not valued to date. The objective of the study is to test the immune response mediated by B cells and T cells, in cases and control samples, through an in vitro model that confronts them with peptides containing the citrullinated-SE sequence. In addition, we will evaluate the association between these results with the clinical features of cases (RA included in the study). Their role as a biomarker, as well as their potential to improve the tests currently available to detect ACPA will be explored.

Interventions

DIAGNOSTIC_TESTResearch new biomarker for RA

Analyze T and B cell response against new citrullinated peptides

Sponsors

Corporacion Parc Tauli
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with RA who meet 1987 ACR criteria Patients with arthritis no RA

Exclusion criteria

* Having an intellectual disability that allows understanding the informed consent to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
T cell response2 yearsProliferation against new citrullinated peptides
B cell response2 yearsDetection antibodies against new citrullinated peptides

Secondary

MeasureTime frameDescription
HLA-DRB12 yearsTyping HLA-DRB1
Rheumatic factor2 yearsTurbidimetric assay
Anti-Citrullinated Peptides Antibodies2 yearsELISA assay

Contacts

Primary ContactEduard Graell, MD. PhD
egraell@tauli.cat+34 937231010

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026